Oberlin et al identified prognostic factors for a patient with metastatic rhabdomyosarcoma. These are overlap with the prognostic factors of Carli et al (see above), who was a co-author for this study. The authors are from multiple institutions in Europe and the United States.
Prognostic factors:
(1) age
(2) site of the primary tumor (favorable vs unfavorable)
(3) involvement of bone and/or bone marrow
(4) number of metastatic sites
|
Parameter |
Finding |
Points |
|
age |
< 12 months |
1 |
|
|
1 to 9 years of age |
0 |
|
|
>= 10 years |
1 |
|
site of primary tumor |
favorable |
0 |
|
|
unfavorable |
1 |
|
bone and/or bone marrow |
no |
0 |
|
|
yes |
1 |
|
number of metastatic sites |
1 or 2 |
0 |
|
|
>= 3 |
1 |
where:
• Favorable sites for the primary tumor: orbit, parameningeal, non-parameningeal, bladder/prostate, paratesticular or vaginal
• Unfavorable sites for the primary tumor: limbs, other sites
total number of poor prognostic findings =
= SUM(points for all 4 sites)
Interpretation:
• minimum score: 0
• maximum score: 4
• Event-free survival (EFS) at 3 years declines as the score increases.
|
Number of Factors |
3 Year EFS |
|
0 |
50% |
|
1 |
42% |
|
2 |
18% |
|
3 |
12% |
|
4 |
5% |
Specialty: Hematology Oncology, Surgery, general, Surgery, orthopedic
